429 related articles for article (PubMed ID: 26602539)
1. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.
Betteridge Z; McHugh N
J Intern Med; 2016 Jul; 280(1):8-23. PubMed ID: 26602539
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
Tansley SL; Simou S; Shaddick G; Betteridge ZE; Almeida B; Gunawardena H; Thomson W; Beresford MW; Midgley A; Muntoni F; Wedderburn LR; McHugh NJ
J Autoimmun; 2017 Nov; 84():55-64. PubMed ID: 28663002
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody evaluation in idiopathic inflammatory myopathies.
Tebo AE
Adv Clin Chem; 2024; 120():45-67. PubMed ID: 38762242
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA; Pak K; Pinal-Fernandez I; Flegel WA; Targoff IN; Miller FW; Rider LG; Mammen AL;
Arthritis Rheumatol; 2023 Sep; 75(9):1668-1677. PubMed ID: 36996276
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic Inflammatory Myopathies.
Balan S; Madan S
Indian J Pediatr; 2023 Nov; ():. PubMed ID: 37919486
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysis.
Mavroudis I; Knights M; Petridis F; Chatzikonstantinou S; Karantali E; Kazis D
J Clin Neuromuscul Dis; 2021 Sep; 23(1):31-38. PubMed ID: 34431799
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory characteristics of idiopathic inflammatory myositis in Saudi patients: A retrospective study in a single tertiary centre.
Alenzi F; Alotaibi J; Alnasser M; Alokaily F
Saudi Med J; 2023 May; 44(5):492-497. PubMed ID: 37182927
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
9. Using autoantibody signatures to define cancer risk in dermatomyositis.
Turnier JL; Kahlenberg JM
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040442
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of anti-cN1A autoantibodies in sporadic inclusion body myositis.
Yamashita S; Tawara N; Zhang Z; Nakane S; Sugie K; Suzuki N; Nishino I; Aoki M
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):1018-1024. PubMed ID: 37451693
[TBL] [Abstract][Full Text] [Related]
11. Update on dermatomyositis.
Tanboon J; Nishino I
Curr Opin Neurol; 2022 Oct; 35(5):611-621. PubMed ID: 35942671
[TBL] [Abstract][Full Text] [Related]
12. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care.
Papadopoulou C; Chew C; Wilkinson MGL; McCann L; Wedderburn LR
Nat Rev Rheumatol; 2023 Jun; 19(6):343-362. PubMed ID: 37188756
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic autoantibody internalization in myositis.
Pinal-Fernandez I; Muñoz-Braceras S; Casal-Dominguez M; Pak K; Torres-Ruiz J; Musai J; Dell'Orso S; Naz F; Islam S; Gutierrez-Cruz G; Cano MD; Matas-Garcia A; Padrosa J; Tobías-Baraja E; Garrabou G; Aldecoa I; Espinosa G; Simeon-Aznar CP; Guillen-Del-Castillo A; Gil-Vila A; Trallero-Araguas E; Christopher-Stine L; Lloyd TE; Liewluck T; Naddaf E; Stenzel W; Greenberg SA; Grau JM; Selva-O'Callaghan A; Milisenda JC; Mammen AL
medRxiv; 2024 Jan; ():. PubMed ID: 38313303
[TBL] [Abstract][Full Text] [Related]
14. Case report of anti-survival motor neuron complex antibody-positive overlap syndrome of diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathies.
Saito M; Uchiyama A; Kim J; Endo Y; Yasuda M; Aoki S; Ikeda Y; Nishino I; Motegi SI
J Dermatol; 2024 Jun; 51(6):e190-e192. PubMed ID: 38149379
[No Abstract] [Full Text] [Related]
15. Insights into juvenile myositis via engineered muscle.
Kim H
Nat Rev Rheumatol; 2023 Sep; 19(9):543-544. PubMed ID: 37495869
[No Abstract] [Full Text] [Related]
16. A Rare Case of NXP-2 Inflammatory Myositis Mimicking GBS.
Sebastian AT; Sagar S; Mittal GK; Sebastian IA; Mathew JJ; Singhdev J; Dwivedi A
Neurol India; 2023; 71(3):582-584. PubMed ID: 37322772
[No Abstract] [Full Text] [Related]
17. Issues in the classification of myositis patients: an ongoing process.
Zanframundo G; Selva-O'Callaghan A; González-Gay MÁ; Montecucco C; Cavagna L
Clin Exp Rheumatol; 2024 Feb; 42(2):225-228. PubMed ID: 38372711
[No Abstract] [Full Text] [Related]
18. Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies.
Choi MY; Satoh M; Fritzler MJ
Curr Opin Rheumatol; 2023 Nov; 35(6):383-394. PubMed ID: 37503636
[TBL] [Abstract][Full Text] [Related]
19. Adverse cutaneous reaction to hydroxychloroquine in a patient with anti-SAE-1-positive dermatomyositis and a history of diffuse large B-cell lymphoma.
Pruneda C; Reddy SA; Buckingham H; Tarbox M
Proc (Bayl Univ Med Cent); 2024; 37(1):158-161. PubMed ID: 38174019
[TBL] [Abstract][Full Text] [Related]
20. Erythrodermic dermatomyositis with anti-TIF1-γ antibodies.
Tang KY; Jin HZ
Int J Dermatol; 2024 Apr; ():. PubMed ID: 38615336
[No Abstract] [Full Text] [Related]
[Next] [New Search]
